CPRX - Catalyst Pharma sees FY20 revenue as high as $118M provides update on product expansion

Catalyst Pharmaceuticals (CPRX) estimates Firdapse annual net revenues for 2020 at ~$118M, an increase of ~16% from 2019. The Board of Directors recently approved an expansion in the company's strategic focus to include acquiring or in-licensing validated technology platforms and earlier stage programs in categories outside of neuromuscular diseases, and to do so CPRX is preparing to invest heavily in R&D.The development of the long-acting formulation of amifampridine phosphate remains on track. A proof-of-concept study evaluating Firdapse as a treatment for Hereditary Neuropathy with Liability to Pressure Palsies ((HNPP)) is scheduled to start in Q1 2021.The company ended 2020 with ~$140M in cash and investments, up ~48% compared 2019. In Catalyst’s appeal of the U.S. District Court’s decision in its suit challenging the FDA's interpretation of Firdapse’ s orphan drug exclusivity, the briefs have been filed, and Catalyst is currently awaiting either a schedule for oral arguments or a decision. Catalyst's

For further details see:

Catalyst Pharma sees FY20 revenue as high as $118M, provides update on product expansion